Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Monika Kutyna
Observed names:
Kutyna, Monika Maria,
M. Kutyna,
Monika M. Kutyna,
Monika M Kutyna,
Monika M. Kutyna
Institution:
South Australian Health and Medical Research Institute
Observed institutions:
South Australia Pathology,
Royal Adelaide Hospital,
University of South Australia,
South Australian Health and Medical Research Institute,
Centre for Cancer Biology,
Central Adelaide Local Health Network,
The University of Adelaide
show all 7
ORCID:
0000-0003-2315-091X
Observed ORCID:
0000-0003-2315-091X
OpenAlex ID:
A5034254010
Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability
2022
·
Daniel Thomas
, Manhong Wu
, et al.
·
Cancer Discovery
·
67
PDF
Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome
2017
·
Deepak Singhal
, Monika M. Kutyna
, et al.
·
Haematologica
·
64
PDF
The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution
2019
·
Deepak Singhal
, Li Yan A. Wee
, et al.
·
Leukemia
·
61
Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer
2021
·
Deepak Singhal
, Christopher N. Hahn
, et al.
·
Leukemia
·
54
TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype
2022
·
Devendra Hiwase
, Christopher Hahn
, et al.
·
Blood
·
43
PDF
Dynamic assessment of RBC‐transfusion dependency improves the prognostic value of the revised‐IPSS in MDS patients
2017
·
Devendra K. Hiwase
, Deepak Singhal
, et al.
·
American Journal of Hematology
·
36
PDF
Therapy-Related Myeloid Neoplasms: Complex Interactions among Cytotoxic Therapies, Genetic Factors, and Aberrant Microenvironment
2024
·
Deepak Singhal
, Monika M. Kutyna
, et al.
·
Blood Cancer Discovery
·
31
A senescence stress secretome is a hallmark of therapy-related myeloid neoplasm stromal tissue occurring soon after cytotoxic exposure
2022
·
Monika M. Kutyna
, Chung Hoow Kok
, et al.
·
Leukemia
·
24
PDF
Red cell autoimmunization and alloimmunization in myelodysplastic syndromes: prevalence, characteristic and significance
2019
·
Rakchha Chhetri
, Li Yan A. Wee
, et al.
·
Haematologica
·
23
Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations
2025
·
Mithun Vinod Shah
, Kevin Hung
, et al.
·
Blood Advances
·
22
PDF
IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation
2024
·
Lih En Hong
, Mihir D. Wechalekar
, et al.
·
Blood
·
20
Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort
2025
·
Mithun Vinod Shah
, Kevin Hung
, et al.
·
Blood Cancer Journal
·
13
PDF
A Personalized Risk Model for Azacitidine Outcome in Myelodysplastic Syndrome and Other Myeloid Neoplasms Identified by Machine Learning Model Utilizing Real-World Data
2023
·
Kirsty Sharplin
, William Proudman
, et al.
·
Cancers
·
8
PDF
Solute Carrier Family 29A1 Mediates In Vitro Resistance to Azacitidine in Acute Myeloid Leukemia Cell Lines
2023
·
Monika M. Kutyna
, Sophie Loone
, et al.
·
International Journal of Molecular Sciences
·
8
PDF
Clonal Diversity of Recurrently Mutated Genes in Myelodysplastic Syndromes
2014
·
Devendra K Hiwase
, Chris N Hahn
, et al.
·
Blood
·
7
Transfusion Dependency Is Associated With Inferior Survival Even In Very Low and Low Risk IPSS-R Patients
2013
·
Devendra K. Hiwase
, Monika M Kutyna
, et al.
·
Blood
·
7
Comparison of World Health Organization and International Consensus Classification Guidelines for Myeloid Neoplasms Harboring TP53-Mutations Using an Independent International Cohort
2023
·
Mithun V Shah
, Monika Kutyna
, et al.
·
Blood
·
5
Duplication on Chromosome 14q Identified in Familial Predisposition to Myeloid Malignancies and Myeloproliferative Neoplasms
2017
·
Christopher N Hahn
, Amilia Wee
, et al.
·
Blood
·
5
Hypomethylating Therapy Does Not Improve Outcome of Therapy-Related Myeloid Neoplasm Including TP53 Mutated and Complex Karyotype Subgroups
2021
·
Rakchha Chhetri
, Kirsty Sharplin
, et al.
·
Blood
·
4
CBL mutations in chronic myelomonocytic leukemia often occur in the RING domain with multiple subclones per patient: Implications for targeting
2024
·
Kelly Lim
, Winnie L. Kan
, et al.
·
PLoS ONE
·
3
PDF
Myeloid neoplasms arising after methotrexate therapy for autoimmune rheumatological diseases do not exhibit poor-risk molecular features
2024
·
Mihir D. Wechalekar
, Lin-Pierre Zhao
, et al.
·
Blood Cancer Journal
·
3
TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome
2022
·
Mithun V. Shah
, Christopher N Hahn
, et al.
·
Blood
·
3
Aberrant Bone Marrow Microenvironment in Therapy Related Myeloid Neoplasm (t-MN)
2019
·
Monika M Kutyna
, Amilia Wee
, et al.
·
Blood
·
3
Rare and Common Germline Variants Contribute to Occurrence of Myelodysplastic Syndrome
2015
·
Christopher N Hahn
, Milena Babic
, et al.
·
Blood
·
3
RBC transfusion dependency refines the Molecular International Prognostic Scoring System for myelodysplastic syndrome
2025
·
Thomas Wiseman
, Michaela Spooner
, et al.
·
Blood Advances
·
2
PDF
Show more works
View as search
Works count:
95
Citation count:
539
H-index:
12
I10-index:
12
Year
Topic
Type
